Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Now that 2022 is behind us, Diabetes in Control presents our top 5 viewed articles from the year. Delve into this content to learn more about diabetes, its effects on individuals with the condition, and a revolutionary treatment breakthrough.
#1 The impact of health coaching with family support on patient activation with diabetes
Investigators assessed whether the Caring Others Increasing Engagement in Patient Aligned Care Teams (CO-IMPACT) intervention improves patient activation, diabetes management, and outcomes compared to standard care. The analysis included 239 patient-supporter dyads who were followed for 12 to 15 months (November 2016 to May 2018).
Check out the impact of CO-IMPACT here.
#2 An effective treatment for type 1 using a blood pressure medication
A study sought to prove the effectiveness of previous studies in humans and to provide clinical insight into the therapeutic effect of a BP medication in newly diagnosed type 1 diabetes patients using proteomics analysis and RNA sequencing.
#3 A study provides insight into how low blood pressure targets should go
A study sought to evaluate the threshold or lowest blood pressure that still supports reduced CVD events. The analyzed study was a prospective epidemiologic cohort analysis; it included 593,196 adults without CVD separated into subgroups based on glycemic status: normoglycemic, prediabetic, and patients with diabetes. The subgroups were further divided into five other categories according to their SBP or DBP readings. Incidence of coronary artery disease or CVD events among the categories was studied. Study population mostly young adults, mean age of 44 normoglycemic, 48 prediabetic, and 52 diabetic.
#4 FDA approves first drug for delaying type 1 diabetes
Recently, the United States Food and Drug Administration granted approval for Tzield (teplizumab-mzwv) injection: a groundbreaking treatment intended to obstruct the progression of stage 2 type 1 diabetes into its more serious form in adults as well as pediatric patients who are 8 years or older.
Here’s what you should know about Tzield.
#5 The effect of a low-carbohydrate diet for HbA1c
Researchers randomly assigned 150 individuals aged 40 to 70 years with elevated untreated HbA1c to a low-carbohydrate intervention (target <40 net g carbohydrates during first three months; <60 net g for months 3 to 6) or usual diet to examine the six-month change in HbA1c. Participants in the low-carbohydrate group also received dietary counseling.
We hope you enjoyed reading these top 5 pieces from Diabetes In Control.